Replies to post #142833 on Biotech Values

[Summer2762]

COU-AA-302 Data Summary & Perspectives on ZYTIGA® (abiraterone acetate) in chemotherapy-naive patients: Recorded Webcast Update for Analysts and Investors

http://www.investor.jnj.com/common/download/download.cfm?companyid=JNJ&fileid=573498&filekey=d69d9c36-61a7-4fb7-927a-fb7c802f3b31&filename=FINAL%20ZYTIGA%20Webcast%20Update%205-31-2012.pdf

Not that the behavior of the patients in the trial will truly reflect the behavior of the patients in the real world, I was nevertheless surprised to see docexatel usage after abi (Zytiga) to be above 50% even at the interim. (Yet another important input if you are an OGXI investor)